A single-arm phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy after standard of chemotherapy for previously treated advanced non-small cell lung cancer.

Yasuhiro KatoYusuke OkumaKageaki WatanabeMakiko YomotaShoko KawaiYukio HosomiTatsuru Okamura

Published in: Cancer chemotherapy and pharmacology (2019)

Nab-paclitaxel may be a safe and effective later-line chemotherapeutic option for previously treated advanced NSCLC after standard of chemotherapies based on other trials.

Keyphrases

advanced non small cell lung cancer
epidermal growth factor receptor
chemotherapy induced
open label
tyrosine kinase
combination therapy
small cell lung cancer
newly diagnosed
locally advanced
radiation therapy
study protocol
iron oxide